Lucid 'A'

Lucid Group's losses widened in 3Q24, and with the upcoming Lucid Gravity SUV, operating expenses and losses are expected to increase in 2025. The company may need to sell more stock in 2025, leading to further shareholder dilution, making it a less compelling investment. Despite a 91% YoY rise in deliveries and increased sales, Lucid Group's valuation is high at 8.4x sales, compared to Rivian's 2.2x.» Mehr auf seekingalpha.com

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Lucid Group (NASDAQ: LCID) on behalf of long-term stockholders following a class action complaint that was filed against Lucid on April 1, 2022 with a Class Period from November 15, 2021 to August 3, 2022. Our investigation concerns whether the board of directors of Lucid have breached their fiduciary duties to the company.» Mehr auf globenewswire.com

NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256 "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" to Molecular Diagnostics Program (MolDX), administered by Palmetto GBA, a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS), to seek coverage for EsoGuard. "This submission is the culmination of many years of persistent hard work by our team and our many clinical research partners, and represents perhaps the most important milestone in Lucid's history," said Lishan Aklog, M.D.» Mehr auf prnewswire.com